Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.F. A. Holmes, Joyce O’Shaughnessy, Michael A. Danso et al.|Journal of Clinical Oncology|2011Cited by 48
Abstract P1-05-20: Validation of the HER2 Activation Response Predictive Signature (HARPS) as a Predictive Biomarker for HER2+ Therapy Response in the Neoadjuvant SettingEmanuel Petricoin, Shridar Ganesan, Julia Wulfkuhle et al.|Clinical Cancer Research|2025Cited by 0